Brief: Omega Therapeutics Reports FDA Clearance Of IND Application For OTX-2002
14/07/2022 21:19
July 14 (Reuters) - Omega Therapeutics Inc OMGA.O :
* OMEGA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND
APPLICATION
FOR OTX-2002, FIRST OMEGA EPIGENOMIC CONTROLLER, FOR MYC DRIVEN
HEPATOCELLULAR CARCINOMA
* OMEGA THERAPEUTICS INC - PHASE 1/2 CLINICAL TRIAL EXPECTED
TO
LAUNCH IN 2H'22 AND WILL EVALUATE SAFETY AND PRELIMINARY
ANTITUMOR ACTIVITY OF OTX-2002
Source text for Eikon: ID:nPn9H0trBa
Further company coverage: OMGA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Omega Liquidating
See all newsBrief: Omega Therapeutics Files For Chapter 11 Bankruptcy In U.S. - Court Filing
Brief: Omega Therapeutics Announces Entry Into New Financing Facilities To Fund Sale Process And Wind Down Of Any Remaining Co Assets
Brief: Omega Therapeutics Receives Notice Of Default Under The Loan And Security Agreement Between Company And Banc Of California
U.S. RESEARCH ROUNDUP- Applied Materials, Disney, Walmart
Brief: Flagship Pioneering Announces Appointment Of Junaid Bajwa As Senior Partner, Head Of United Kingdom, And Science Partner For Pioneering Intelligence